Apr 24 |
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
Apr 24 |
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
|
Apr 22 |
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
|
Apr 17 |
Alkermes to Report First Quarter Financial Results on May 1, 2024
|
Apr 17 |
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
|
Apr 16 |
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
Apr 11 |
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
|
Apr 11 |
Alkermes' Innovations Are Transforming Mental Health Treatments
|
Apr 9 |
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
|
Apr 9 |
Alkermes plc: Collecting The Fruits Of The 2023 Spinoff
|